Overview

Bioequivalence Study of Two Different Formulations of N-acetyl-cysteine (NAC)

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Study primary Objective: - To evaluate the bioequivalent rate (Cmax) and extent (AUC0-t) of absorption of N-acetyl-cysteine 600 mg uncoated tablets vs. N-acetyl-cysteine 600 mg film-coated tablets (NAC) in healthy male and female volunteers. Study secondary objectives: - To describe the pharmacokinetic (PK) profile of NAC in plasma after single dose administration of NAC 600 mg uncoated tablets vs. NAC 600 mg film-coated tablets; - to collect safety and tolerability data after single dose administration of NAC 600 mg uncoated tablets vs. NAC 600 mg film-coated tablets.
Phase:
Phase 1
Details
Lead Sponsor:
Zambon SpA
Treatments:
Acetylcysteine
N-monoacetylcystine